Gabapentin Capsule
Product Images NDC 71335-2280

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2280). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula to calculate creatinine clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H). This diagram represents the molecular framework of the active ingredient gabapentin.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decreasing pain score trend for gabapentin compared to relatively stable scores for placebo.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph depicting mean pain scores over a 7-week period, comparing placebo and Gabapentin at dosages of 1800 mg/day and 2400 mg/day. The x-axis represents weeks, starting from baseline to week 7, and the y-axis shows pain scores ranging from 0 to 10. The study includes a 3-week dose titration period and a 4-week fixed dose period.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses across two studies. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo and 32% and 34% for GBP 1800 mg and 2400 mg, respectively. Statistical significance is indicated with p-values (p < 0.01 and p < 0.001).*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot showing the difference percentage on the y-axis versus daily dose in mg on the x-axis for Gabapentin. The chart compares results from three studies labeled a, b, and c at various doses (600, 900, 1200, and 1800 mg). Each study is represented by distinct markers and letters indicating statistical differences.*

FDA Label Image

Label (Lbl713352280)

Label for Gabapentin Capsules, USP 300 mg by Bryant Ranch Prepack. The label shows the NDC number 71335-2280-1, a package size of 1000 capsules, and indicates oral capsule form. It includes storage instructions and a barcode. Manufacturer is ACI Healthcare Limited, with repackaging by Bryant Ranch Prepack.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.